Hims and Hers Health Inc vs Novo Nordisk A/S — how do they compare? Hims and Hers Health Inc trades at $30.81 (market cap $7.12B), while Novo Nordisk A/S trades at $46.2 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 29.2× Hims and Hers Health Inc's market cap, and Novo Nordisk A/S pays a 3.81% dividend while Hims and Hers Health Inc pays none. Which is the better fit depends on your goals.
| HIMS | NVO | |
|---|---|---|
Market Cap | $7.12B | $207.85B |
Sector | Health | Health |
52-Week High | $62.76 | $63.98 |
52-Week Low | $14.52 | $35.29 |
Enterprise Value | $7.82B | $222.55B |
Dividend Yield | — | 3.81% |
Signals from Pluang's Aura AI — not financial advice
HIMS stock trades at $30.00, down 5.57% amid mixed Q2 2026 results. Revenue growth remains strong, with a 2026 outlook raised to $3.1B-$3.3B, but profitability is pressured by margin compression and a wider-than-expected quarterly loss. Technical indicators are neutral to bearish, with the price near key support at $30. Recent news highlights an FTC investigation and class-action lawsuits as headwinds.
The investment outlook is cautious. Growth prospects from subscriber gains and AI integration are offset by significant margin challenges and regulatory risks. Analyst consensus is a Hold with a $33.00 price target, suggesting limited near-term upside amid profitability concerns and negative free cash flow trends.
Novo Nordisk (NVO) trades at $46.28, down 3.05% today, with technical indicators showing neutral signals. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $0.96 versus $0.77 estimate, continuing a pattern of earnings outperformance. Revenue growth remains solid with 2025 revenue reaching $309.1B and net income margin of 33.14%. Analyst sentiment remains positive with 57.9% recommending Buy, though recent news highlights competitive pressures from Eli Lilly in the GLP-1 market.
NVO presents a compelling investment case with robust profitability metrics including 59.82% ROE and attractive valuation at 11.62 P/E. However, increasing competition in weight-loss drugs and pricing pressures create headwinds. The stock's current technical neutrality suggests potential consolidation near current levels, with fundamental strength supporting long-term growth prospects despite near-term competitive challenges.
Trailing returns across standard periods
Latest headlines on both assets
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →